OBJECTIVES: The purpose of this multicentre cohort study was to examine the relationship between antiplatelet therapy (APT) at the time of coronary artery bypass grafting (CABG) and postoperative bleeding complications, transfusion requirements and adverse cardiovascular events.
INTRODUCTION
Patients referred for coronary artery bypass grafting (CABG) are commonly treated with antiplatelet agents, notably aspirin and oral adenosine diphosphate (ADP)-receptor antagonists. Long-term aspirin therapy is the standard of care in patients with coronary artery disease, whereas concomitant treatment with oral ADP-receptor antagonists is recommended for patients with recent acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) [1] [2] [3] .
The use of antiplatelet agents at the time of CABG carries both benefits and risks. These drugs are effective in reducing ischaemic events in high-risk patients awaiting surgery [4, 5] . Unfortunately, they also aggravate the bleeding tendency associated with cardiac surgery [5] [6] [7] [8] .
As the indications for oral antiplatelet therapy (APT) expand, physicians frequently have to make decisions about the timing of CABG in patients exposed to these drugs. There is a consensus that the oral ADP-receptor antagonist clopidogrel should be discontinued before CABG, where possible. On the other hand, most cardiac surgeons consider the use of aspirin before CABG as relatively safe. Current international guidelines recommend discontinuing aspirin 2-10 days prior to elective cardiac surgery, while they advocate the withholding of clopidogrel for at least 5 days before elective CABG [9] [10] [11] .
These guidelines are notably based on limited evidence. Although there is an abundance of analyses dealing with preoperative APT, most studies were small and single-centre analyses. The few larger studies had contradictory findings.
The aim of this study was to verify the accuracy of existing international guidelines on preoperative APT with a large multicentre analysis. The authors hypothesized that patients exposed to aspirin or clopidogrel at the time of CABG had increased postoperative bleeding and transfusion requirements with subsequent negative effects on postoperative outcomes.
MATERIALS AND METHODS

Study design
This multicentre cohort study was comprised of 6350 consecutive CABG patients. The three major cardiac centres in Western Denmark participated in the study. Western Denmark has a population of 3.3 million, representing 60% of the total Danish population.
Patients who underwent CABG from 1 April 2006 through 31 December 2011 were included. Eligible procedures were either isolated CABG or CABG combined with aortic valve replacement, regardless of the urgency status. Both on-pump and off-pump procedures were included. To reduce confounding, we chose to exclude patients preoperatively treated either with intravenous glycoprotein (GP) IIb/IIIa inhibitors or with factor Xa inhibitors.
Patients exposed to aspirin or clopidogrel within 5 days preceding CABG were assigned to an APT group. The remaining patients represented the control group. To adjust for baseline differences, APT group patients were matched with control group patients by a 1:1 ratio. The APT group was then further divided into an aspirin, a clopidogrel or a dual APT subgroup, depending on whether patients had been treated with one or both drugs prior to surgery.
Material
We used the Western Denmark Heart Registry (WDHR) to identify all CABG patients operated on during the study period. Data from the registry were retrieved and analysed in 2012.
The WDHR gathers information on patients undergoing cardiac surgery at the three participating hospitals [12] . Reporting to this regional, web-based registry has been mandatory since 1999. Detailed patient-, surgery-, anaesthesia-and intensive care-related data are reported, as are data on in-hospital complications and 30-day mortality. Since April 2006, all data related to this study have been obligatory. Data quality is ensured by automatic validation rules at data entry, combined with systematic validation procedures and random spot checks of data after entry. Any relevant missing data were obtained from patient files and other databases, such as the Danish Transfusion Registry, which retain information on all blood transfusions in Denmark.
Perioperative procedures
Routine surgical and cardioprotective techniques were used, including crystalloid or cold blood cardioplegia. The closed cardiopulmonary bypass systems consisted of tubing with a surface-modifying additive coating, an arterial filter with heparin coating, a hollow-fibre membrane oxygenator with a surfacemodifying additive coating and a venous and cardiotomy reservoir. Most of the patients were maintained normothermic or slightly hypothermic. Whether coronary artery bypass surgery was done on-or off-pump was left to the discretion of the attending surgeon.
The majority of patients received either tranexamic acid or aprotinin as part of blood conservation strategies. Postoperative autotransfusion of unwashed shed mediastinal blood was routinely used, with the exception of one centre, which abandoned this technique in 2007. This change in treatment influenced <10% of evaluated patients. Preoperative autologous blood donation, acute normovolaemic haemodilution, cell saving or haemofiltration were rarely applied.
Transfusions of allogeneic blood components were given at the discretion of the attending anaesthesiologist or surgeon. Indications for allogeneic transfusion were based on routine laboratory measurements of activated partial thromboplastin time, activated clotting time and international normalized ratio, as well as on fibrinogen, haemoglobin and haematocrit levels. Furthermore, the use of allogenic blood products was affected by haemodynamic and physiological data, the rate of blood loss and the existence of concomitant diseases. The target of haemoglobin level tended to be higher with increasing patient age. During the study period, thrombelastometry-guided blood component therapy became available at two of the three participating centres.
Patient and outcome characteristics
Patients and procedures were characterized primarily by European System for Cardiac Operative Risk Evaluation (EuroSCORE) variables [13] .
The primary outcome parameters were the association between preoperative use of aspirin and clopidogrel and postoperative bleeding volumes, perioperative transfusion requirements and reoperation rates. Furthermore, we analysed the relationship between exposure to the two drugs and postoperative 30-day mortality, need for dialysis, myocardial infarction and stroke.
Postoperative bleeding was specified as the total amount of chest tube drainage until chest drain removal or discharge from the intensive care unit, depending on which occurred first. Severe postoperative bleeding was defined as postoperative chest tube drainage >1000 ml. Transfusion requirements were registered as the total amount of packed red blood cells, fresh frozen plasma and platelet concentrates transfused intraoperatively, as well as during the postoperative stay in the intensive care unit.
Myocardial infarction had to fulfil the following criteria: the occurrence of a new q-wave and/or a creatinin kinase myocardial band >100 µg/l (more than five times the upper level). Stroke was a combined outcome, defined as registered transitory ischaemic attack (symptoms lasting <24 h) or registered cerebrovascular attack (symptoms lasting >24 h). We did not distinguish between haemorrhagic and ischaemic stroke. Reoperation was specified as the return to the operating room due to bleeding or cardiac tamponade. We registered postoperative dialysis without differentiating between the actual mode of renal replacement therapy or the precise indication for dialysis.
Data on 30-day mortality were obtained from the Danish Civil Registration System. The system keeps updated records on vital status, date of death, residence and migration of all Danish citizens. The study was approved by the Danish Data Protection Agency (1-16-02-194-12) .
Statistical analysis
Continuous variables were described using mean or median values. Categorical variables were described as percentages. Analyses to compare continuous data were done using the independent samples t-test or Mann-Whitney test depending on whether the data are parametric/non-parametric together with analysis of variance (ANOVA) or Kruskal-Wallis where appropriate. Categorical variables were compared using the χ 2 test. A P-value of <0.05 was considered to be statistically significant.
Patients in the APT and control groups were matched by a 1:1 ratio that showed accordance in 11 variables: sex, EuroSCORE age score, serum creatinine >200 µmol/l, preoperative dialysis, insulin-dependent diabetes, previous cardiac surgery, on-/ off-pump surgery, total scores of EuroSCORE patient factors, cardiac factors, procedure factors and total EuroSCORE. If more than one match existed, the best match for the department or the year of surgery was chosen.
To adjust for remaining baseline differences between the groups, multivariable analyses were performed. We used multiple logistic regression models for the dichotomous outcomes of severe postoperative bleeding, death, myocardial infarction, stroke and need for dialysis. The adjusted odds ratio (OR) and corresponding 95% confidence intervals (95% CI) were computed for these variables. Potential confounders were entered into the models if they were clinically relevant or showed statistical significance at P < 0.20 during the univariate analysis between the two groups.
Statistical analyses were performed with MedCalc, version 12.3.0 (MedCalc Software, 9030 Mariakerke, Belgium).
RESULTS
From the WDHR database, 6544 eligible patients were identified. Forty-seven had to be excluded because of missing data or loss to follow-up. One hundred and forty-seven patients were excluded because of preoperative treatment either with GP IIb/ IIIa inhibitors or with factor Xa inhibitors, thus leaving 6350 patients for analysis (Fig. 1) . The majority (n = 5231; 82%) underwent isolated CABG surgery, whereas 1119 (18%) underwent CABG combined with aortic valve replacement.
The APT group consisted of 1846 (29%) patients who, by definition, had been exposed to aspirin or clopidogrel within 5 days before CABG. Of them, 1291 (20% of all patients) had been treated with aspirin alone, 108 (2%) had been exposed to clopidogrel alone and 447 (7%) had been exposed to both drugs within 5 days before surgery. These patients were assigned to the aspirin, clopidogrel and dual APT subgroups, respectively. The control group consisted of the remaining 4504 (71%) patients who had been exposed neither to aspirin nor to clopidogrel within 5 days before surgery (Fig. 2) .
The baseline characteristics of patients in the control and the APT groups are summarized in Table 1 . There were no differences in the duration of extracorporeal circulation or the fraction of patients undergoing on-vs off-pump surgery.
Prior to matching, APT group patients were more likely to have suffered a recent myocardial infarction or to present with unstable angina pectoris (requiring treatment with intravenous nitrates preoperatively). Additionally, APT patients underwent acute surgery (surgery done before the next working day after referral) more frequently, experienced more often isolated CABG and were more likely to have a reduced left ventricular ejection fraction (<30%) and pulmonary hypertension (systolic pulmonary artery pressure >60 mmHg). Furthermore, antifibrinolytics were used more often in the APT group. Nonetheless, the majority of patients in the APT group (82.5%) were classified as elective cases.
After matching, 1132 pairs of patients remained, the only significant differences being a slightly longer extracorporal circulation time and a slightly greater use of antifibrinolytic drugs in the APT group. The following results relate to the matched patients, if not otherwise indicated.
Patients in the APT group had greater mean bleeding volumes than control group patients (946 vs 775 ml; P < 0.0001; independent samples t-test). In a subgroup analysis, mean bleeding volumes were significantly lower in the control group compared with the aspirin subgroup (896 ml), the clopidogrel subgroup (989 ml) and the dual APT subgroup (1112 ml; Fig. 3 ). No significant difference was identified between the aspirin subgroup and the clopidogrel subgroup.
Severe postoperative bleeding (>1000 ml) occurred significantly more frequently in the APT group than in the control group (27.5 vs 20.4%; P = 0.0001). Multivariate analysis revealed that clopidogrel use, increasing age and surgery at one of the participating centres were independent risk factors for severe postoperative bleeding, while the use of aspirin was not (Table 2) . On the other hand, off-pump surgery and the perioperative use of tranexamic acid were associated with a lower risk of severe postoperative bleeding.
Overall, reoperation rates were similar in the APT and control groups (5.5 vs 4.0%; P = 0.157). In a subgroup analysis, there was no significant difference between the aspirin subgroup and the control group (Table 3 ). In the clopidogrel subgroup, however, patients were reoperated significantly more often than control group or aspirin subgroup patients.
Transfusion rates were lowest in the control group, in which less than one-third of the patients received any blood products (Table 3) . They were greatest in the dual APT subgroup, in which more than half of the patients were transfused. Patients exposed to aspirin received more packed red blood cells, more fresh frozen plasma and more platelet concentrates than those in the control group. Patients in the clopidogrel subgroup received more blood products than those in the control group and, similarly, more blood products than those in the aspirin subgroup.
No difference could be found in terms of 30-day mortality, myocardial infarction, stroke and need for dialysis between the APT and control groups (Table 4 ). An odds ratio analysis could likewise not demonstrate any difference in these adverse postoperative outcomes (Table 5 ).
DISCUSSION
The overall findings in this study were that patients exposed to antiplatelet drugs at the time of CABG had greater postoperative bleeding volumes and greater transfusion requirements. These findings were expected and in accordance with the authors' hypothesis.
Another finding was that the exposure to clopidogrel, not to aspirin, was associated with greater reoperation rates and was an independent risk factor for severe postoperative bleeding. One could argue that aspirin may also have been an independent risk factor for severe postoperative bleeding, if we had defined this outcome measure differently. Our definition (chest tube drainage volumes >1000 ml) was based on clinical experience and, therefore, somewhat arbitrarily chosen. It is important to note, however, that we also identified an increased rate of reoperation in patients exposed to clopidogrel. The decision to reoperate naturally suggests and indicates a status of severe bleeding. Thus, the increased bleeding risk related to clopidogrel is likely to be real.
Surprisingly, mean bleeding volumes were not significantly different in the aspirin and clopidogrel subgroups. Although there was a trend towards greater bleeding in patients exposed to clopidogrel alone, this finding became not statistically significant.
One reason for this is presumably the low number of patients in the clopidogrel subgroup. Another explanation could be the interindividual variability in platelet response to clopidogrel. Previous reports have demonstrated that as many as 30% of patients are resistant to the actions of clopidogrel [14] . Therefore, mean postoperative bleeding volumes in clopidogrel-exposed patients are probably misleading. A great fraction of those patients might not experience an antiplatelet effect at all, while the remaining patients experience a potent antiplatelet effect with a greater bleeding risk.
In our study, transfusion requirements followed the severity of postoperative bleeding. Although mean chest drainage volumes were similar in the aspirin and clopidogrel subgroups, patients in the clopidogrel subgroup received significantly more blood products than those in the aspirin subgroup. One explanation for this is perhaps the greater risk of severe postoperative bleeding and reoperation in clopidogrel-exposed patients, which might be accompanied by massive transfusion. Another explanation might be the presence of treatment bias. In clinical practice, many cardiac anaesthesiologists assume that patients exposed to clopidogrel convey a higher risk of severe postoperative bleeding. Therefore, they might tend to transfuse these patients earlier and more aggressively. We also demonstrated that dual APT at the time of CABG is associated with greater transfusion requirements when compared with exposure to a single antiplatelet drug. Although this effect is arguably causal, the observational design of our study does not allow us to draw this conclusion. Patients undergoing CABG, despite on-going dual APT, are often patients presenting with ACS. Consequently, the need for transfusion may have been affected by the clinical state of the patients before surgery and the emergency status of the operation. Miceli et al. [15] , on the other hand, demonstrated that dual APT is an independent predictor of severe postoperative bleeding, reoperation and increased transfusion requirements after CABG.
Past research in this area has yielded conflicting results, and some findings are inconsistent with our analysis. In one observational study, Bybee et al. [16] analysed 1636 consecutive CABG patients and used propensity scores to adjust for differences between groups. They could not demonstrate increased bleeding complications, but did, however, observe a decreased overall mortality in the aspirin group.
On the other hand, Jacob et al. [17] , who studied data from 4143 CABG patients operated at the Cleveland Clinic, observed higher transfusion requirements in aspirin exposed patients, without any effect on reoperation rates or mortality.
We showed a higher bleeding risk and greater reoperation rates in patients treated with clopidogrel at the time of CABG. The investigators of the Clopidogrel for the Reduction of Events During Observation (CREDO) trial could not, however, demonstrate a significant increase in bleeding complications in clopidogrel-exposed PCI patients requiring CABG [18] . Likewise, no increase in severe postoperative bleeding or transfusion requirements were seen in PCI patients exposed to clopidogrel within 5 days before CABG in the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial [4] .
Other researchers, however, reached the same conclusions as we did in our present study: Nijjer et al. [19] conducted a meta-analysis on the effect of clopidogrel use before CABG and demonstrated greater transfusion requirements and reoperation rates. At the same time, they criticized the low quality of the analysed studies. Mehta et al. [20] used the CRUSADE registry (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines) to compare 739 patients exposed to clopidogrel within 5 days before CABG with those who were not. They observed a significant increase in transfusion requirements after clopidogrel exposure. Likewise, the investigators of a large observational multicentre study by Berger et al. [7] found significant increases in major bleeding and reoperation rates in clopidogrel-treated CABG patients.
Finally, we could not demonstrate differences in terms of death, myocardial infarction, stroke or renal dysfunction. The study by Miceli et al. [15] , on the other hand, showed an increased risk of myocardial infarction in CABG patients on dual APT.
The future of antiplatelet therapy
Clopidogrel has long been the antiplatelet agent of choice for the prevention of stent thrombosis. With the emergence of newer ADP-receptor antagonists, it would not seem unlikely that clopidogrel will be replaced as a first-choice drug. The thirdgeneration thienopyridine ticagrelor has a more reliable effect, a quicker onset of action and a shorter half-life in the blood stream. In the PLATO trial, the risk of non-procedure-related bleeding after exposure to ticagrelor was increased when compared with clopidogrel, although there was no difference in CABG-related major bleeding [21] . As a shorter acting agent, ticagrelor might allow for earlier cardiac surgery. A subgroup analysis in the PLATO trial showed a decrease in all cause mortality in the ticagrelor group, thereby further emphasizing a change in treatment regimes in the future [22] .
In situations where potent antiplatelet action is desirable before CABG, newer intravenous ADP-receptor antagonists with rapid offset of action allow for a 'bridging' therapy, when longer acting oral antiplatelet agents can be discontinued [23] . This may lead to a declining exposure to oral antiplatelet drugs in the immediate preoperative period.
Limitations of the study
This is a multicentre study using detailed data, with almost complete follow-up. The sample size is comparatively large. Our study also has important limitations. The major limitation is that it is not a randomized controlled trial. The patients in the control group were more likely to be stable elective patients, whereas patients exposed to platelet inhibitors were more often declared as urgent with unstable angina or a recent myocardial infarction. Consequently, the clinical state of the patients may have impacted on the occurrence of bleeding complications. Even though a matched-pair analysis was performed to compare the APT with control group, the individual subgroups were not matched. Furthermore, although multivariable analysis was used to adjust for confounders, residual confounders cannot be obviously ruled out.
Secondly, we limited our analysis to patients who actually underwent CABG, not patients scheduled for CABG. As a consequence, we have no information about the incidence of ischaemic events in the preoperative period, where ongoing APT offers the greatest advantages.
Another limitation is that we retrieved all our data from a clinical registry. The quality of our study data is, therefore, dependent on the accuracy at data entry. Here, inaccuracies may occur, particularly when several re-explorations or a prolonged stay on the intensive care unit complicates the postoperative course. However, the data from the WDHR are prospectively registered and have proved valid in earlier studies [12] .
Furthermore, we neither registered the precise timing of APT discontinuation nor the precise aspirin or clopidogrel dose the study patients had received. This is of clinical importance, as the magnitude of platelet inhibition is dependent on these factors.
CONCLUSIONS
The results of our analysis suggest that the preoperative use of antiplatelet drugs is associated with increased postoperative bleeding and greater transfusion requirements after CABG.
Clopidogrel exposure prior to CABG is associated with greater reoperation rates and is an independent risk factor for severe postoperative bleeding. In accordance with existing international guidelines, we recommend a washout-period for clopidogrel prior to cardiac surgery when clinically feasible. Aspirin treatment before CABG appears to be relatively safe. Nonetheless, we agree with present international guidelines that aspirin should be stopped several days prior to CABG in purely elective cases, where the bleeding risk probably outweighs the risk of ischaemic complications.
We could not demonstrate a negative effect of oral antiplatelet drugs at the time of CABG on 30-day mortality or the occurrence of major adverse postoperative cardiovascular events and suggest that patients with a high risk of ischaemic events proceed with surgery without waiting for an antiplatelet drugfree period.
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